Top Markets
Coin of the day
Relmada Therapeutics, Inc. Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD
주식 순위 #13828
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company... Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
주가
$4.36
시가총액
$457.32M
변동 (1일)
0.69%
변동 (1년)
289.29%
국가
US
거래 Relmada Therapeutics, Inc. (RLMD)

카테고리

Relmada Therapeutics, Inc. (RLMD)의 EPS
2026 기준 EPS TTM: 0
Relmada Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Relmada Therapeutics, Inc.의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH